Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Assisted Reproduction
Biopharmaceutical company receives CE Mark for Cumulase
January 27th, 2005
Halozyme Therapeutics, Inc., a development stage biopharmaceutical company developing and commercializing recombinant human enzymes, has received CE (European Conformity) Mark approval for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The CE Mark demonstrates that the company is in compliance with the applicable European Union (E.U.) directives and allows the company to market Cumulase throughout the E.U. Halozyme anticipates launching Cumulase early in the first quarter of 2005. "This is a major milestone for Halozyme that achieves our stated goal of obtaining regulatory clearance for Cumulase...
Source: Women's Health Weekly (2005-01-27)
|
